ANVS

Annovis Bio Inc

ANVS.US annovisbio.com
Healthcare · Biotechnology
1.19
-0.03 (-2.46%)
USD · NYSE
52-week range
1.17
5.50
Trading at 0% of the 52-week range
Market Cap
50.70M
P/E Ratio
0.00
Forward P/E
0.00
Book Value
-0.10
Div. Yield
N/A
% Institutions
27.91%
% Insiders
6.71%

1 Year

-48.5%

3 Year

-89.7%

10 Year

-87.6%
Description

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in open-label phase 3 to treat parkinson's disease. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia. Annovis Bio, Inc. was incorporated in 2008 and is headquartered in Malvern, Pennsylvania.

Company Information

▼
Company Name
Annovis Bio Inc
Sector
Healthcare
Industry
Biotechnology
Exchange
NYSE
ISIN: US03615A1088
CIK: 0001477845
CUSIP: 03615A108
Currency: USD
Full Time Employees: 7
Phone: 484 875 3192
Website: annovisbio.com
Fiscal Year End: December
IPO Date: Feb 12, 2010
Description:

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in open-label phase 3 to treat parkinson's disease. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia. Annovis Bio, Inc. was incorporated in 2008 and is headquartered in Malvern, Pennsylvania.

Address:

101 Lindenwood Drive, Malvern, PA, United States, 19355

People

▼

Directors & Officers

Name Title Year Born
Dr. Maria L. Maccecchini Ph.D. Founder, Acting CFO, CEO, President & Executive Director 1951
Dr. Cheng Fang Ph.D. Chief Scientific Officer NA
Ms. Eve M. Damiano M.S., RAC Senior Vice President of Regulatory Operations NA
Mr. Blake Jensen M.B.A. Head of Quality NA
Ms. Hilda Maibach Senior Vice President of Statistics NA

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Apr 02, 2026 Michael B Hoffman N/A Purchase 713.80K $2.10 $1.50M
Dec 08, 2025 Michael B Hoffman N/A Purchase 45.00K $4.31 $193.95K
Nov 24, 2025 Michael B Hoffman N/A Purchase 39.20K $4.08 $159.94K
Nov 21, 2025 Michael B Hoffman N/A Purchase 20.00K $3.50 $70.00K
Nov 14, 2025 Michael B Hoffman N/A Purchase 15.00K $2.11 $31.65K
Oct 28, 2025 Maria-Luisa Maccecchini N/A Purchase 97.56K $2.05 $200.00K
Oct 28, 2025 Michael B Hoffman N/A Purchase 975.61K $2.05 $2.00M

Shareholders

▼

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
Empery Asset Management, LP 2.40M Jun 30, 2026 5.64% $5.17 0.00%
Marshall Wace Asset Management Ltd 1.19M Mar 31, 2026 2.79% $0.00 63.60%
Vanguard Capital Management, LLC 872.38K Mar 31, 2026 2.05% $0.00 0.00%
Two Sigma Investments LLC 627.66K Mar 31, 2026 1.47% $0.00 13.74%
Renaissance Technologies Corp 347.60K Mar 31, 2026 0.82% $0.00 0.00%
Geode Capital Management, LLC 247.51K Mar 31, 2026 0.58% $0.00 11.43%
Susquehanna International Group, LLP 218.34K Mar 31, 2026 0.51% $0.00 -28.01%
Northern Trust Corp 141.73K Mar 31, 2026 0.33% $0.00 17.27%
BlackRock Inc 139.53K Mar 31, 2026 0.33% $0.00 0.00%
Vanguard Fiduciary Trust Co 132.04K Mar 31, 2026 0.31% $0.00 0.00%
Quadrature Capital Limited 90.88K Jun 30, 2026 0.21% $0.00 0.00%
State Street Corp 77.74K Mar 31, 2026 0.18% $0.00 5.00%
Group One Trading, LLC 69.66K Mar 31, 2026 0.16% $0.00 0.78%
First National Trust Co 60.00K Jun 30, 2026 0.14% $0.00 50.00%
Sherry Group Inc 57.27K Jun 30, 2026 0.13% $0.10 0.00%
GSA Capital Partners LLP 49.90K Jun 30, 2026 0.12% $0.01 9.87%
Greenwich Wealth Management LLC 48.40K Jun 30, 2026 0.11% $0.00 2.98%
Wescott Financial Advisory Group, LLC 41.61K Jun 30, 2026 0.10% $0.01 0.00%
Bridgeway Capital Management, LLC 37.68K Mar 31, 2026 0.09% $0.00 54.41%
Oakmont Partners, LLC 29.00K Jun 30, 2026 0.07% $0.00 11.54%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Vanguard MStar Total Stk Mkt Idx Invest 1.22M 2.86% ▲ 0.00% Jul 31, 2026
2 Vanguard Institutional Extnd Mkt Idx Tr 393.89K 0.92% ▲ 0.00% Jul 31, 2026
3 Fidelity Extended Market Index 153.14K 0.36% ▼ 0.20% Jul 31, 2026
4 iShares Micro-Cap ETF 102.65K 0.24% ▼ 1.95% Aug 31, 2026
5 Extended Equity Market Fund E 72.23K 0.17% ▲ 440.19% Dec 31, 2025
6 Blackrock Extended Mkt Fund CF 72.23K 0.17% ▲ 0.00% May 31, 2026
7 Extended Equity Market Fund B 72.23K 0.17% ▲ 440.19% Dec 31, 2025
8 BlackRock Extended Equity Market Fund K 61.39K 0.14% ▼ 0.18% Jun 30, 2026
9 Fidelity Series Total Market Index 45.69K 0.11% ▲ 36.72% Jul 31, 2026
10 Northern Trust Extended Eq Market Idx 38.29K 0.09% ▲ 41.22% Jun 30, 2026

Financial Highlights

▼
Market Cap: $50.70M
Book Value: $-0.10
Earnings/Share: $-1.71
Profit Margin: 0.00%
Operating Margin: 0.00%
ROA (TTM): -142.36%
ROE (TTM): -703.68%
Revenue (TTM): $0.00
Revenue/Share (TTM): $0.00
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 0.00%

Valuation Metrics

Enterprise Value: $33.25M
Trailing P/E: 0.00
Forward P/E: 0.00

Shares Statistics

Shares Outstanding: 42.61M
Shares Float: 35.32M
% Insiders: 6.71%
% Institutions: 27.91%
Short % Float: 12.79%

Stock Price History

▼

1 Year Price History

3 Years Price History

10 Years Price History

Financial Charts

▼

Revenue, Net Income & Operating Cash Flow (Yearly)

Revenue, Net Income & Operating Cash Flow (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

▼
Open full waterfall
Line Item
Step Type
Value
Revenue
adjust
$0.00
Gross Profit
subtotal
$0.00
SG&A
adjust
$-4.48M
R&D
adjust
$-25.22M
Operating Income
subtotal
$-29.70M
Other / Non-Operating Items
adjust
$841.06K
Net Income
subtotal
$-28.85M

Earnings Per Share (EPS) History

▼

Financial Ratios

▼

📦 Raw API Data (JSON Explorer)

▼

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about ANVS.US!